EGLT Gets Long Awaited FDA Approval, PTCT Breathes Easy, GLMD On Track

Shares of PTC Therapeutics Inc. (PTCT) rose over 10% on Monday, following the European Commission's positive decision granting annual renewal of the conditional marketing authorization for its treatment of nonsense mutation Duchenne muscular dystrophy, Translarna.

from RTT - Biotech http://ift.tt/2jxPhPH
via IFTTT